Results 71 to 80 of about 3,775 (204)

The Concise Guide to PHARMACOLOGY 2025/26: Transporters

British Journal of Pharmacology, Volume 182, Issue S1, Page S404-S496, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander, Alasdair J. Gibb, Eamonn Kelly, Alistair A. Mathie, Chloe J. Peach, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Christopher Southan, Jamie A. Davies, Laura Amarosi, Catriona M. H. Anderson, Philip M. Beart, Stefan Broer, Paul A. Dawson, Gergely Gyimesi, Bruno Hagenbuch, James R. Hammond, Jules C. Hancox, Michal Hershfinkel, Ken‐ichi Inui, Yoshikatsu Kanai, Stephan Kemp, Edmund R. S. Kunji, Gavin Stewart, Sotiria Tavoulari, David T. Thwaites, Tiziano Verri   +28 more
wiley   +1 more source

Management of Clostridium difficile in a developing nation

Archives of Pharmacy Practice, 2016
Introduction: Clostridium difficile is the most important definable cause of healthcare acquired diarrhea. Recommended treatments for Clostridium difficile infection (CDI) are metronidazole, oral vancomycin and fidaxomicin (a new narrow spectrum ...
Azadeh Nasrollah, Shiva Hashemi, Parvin Talebloo, Mehdi Rajabi, Syed Azhar Syed Sulaiman, Usman Abubakar   +5 more
doaj   +1 more source

New Structure Activity Relationship Insight into the Role of the C‐3 Extension on Rifamycin Antimycobacterial Activity

ChemMedChem, Volume 20, Issue 22, November 18, 2025.
Rifamycin analogues with variably functionalized C‐3 extensions provide new insight into the role of this region for MTb inhibitory activity. In addition to potentially optimizing target engagement, this region can also be used to modulate physicochemical properties, an important consideration for optimizing antimycobacterial activity.
Clinton G. L. Veale, Ewelina Smolarz, Aleksandra Leśniewska, Krystian Pyta, Piotr Przybylski   +4 more
wiley   +1 more source

Bezlotoxumab as Treatment for Recurrent/Chronic Clostridioides difficile Infection in Pediatric Stem Cell Transplant Recipients: A Multi‐Institutional Experience

Pediatric Blood &Cancer, Volume 72, Issue 10, October 2025.
ABSTRACT Clostridioides difficile infection (CDI) represents a significant health risk to pediatric stem cell transplant (SCT) patients. In these patients, recurrent CDI is common, requiring prolonged antibiotic usage and increased hospitalization. Bezlotoxumab, a monoclonal antibody that targets the toxin responsible for CDI, has demonstrated efficacy
Aaron E. Fan, Shaikha Alqahtani, Natalie Dailey Garnes, Priti Tewari, Demetrios Petropoulos, Sajad Khazal, Kris Mahadeo, Paige DePriest, Irtiza N. Sheikh   +8 more
wiley   +1 more source

Gastrointestinal Infection Before Immune Checkpoint Inhibition Hinders Treatment Efficacy and Increases the Risk of Colitis

Cancer Medicine, Volume 14, Issue 15, August 2025.
ABSTRACT Background Gastrointestinal (GI) infections, which often result in or stem from intestinal dysbiosis, can affect the efficacy of immune checkpoint inhibitors (ICIs) and increase the risk of adverse effects, such as colitis. In this study, we explored the impact of GI infections before initiation of ICI therapy on the incidence and severity of ...
Malek Shatila, Kian Abdul‐Baki, Andres Urias Rivera, Kei Takigawa, Irene Jeong‐Ah Lee, Andrew Sullivan, Tanvi Gupta, Linfeng Lu, Raakhi Menon, Ayesha Khan, Hamza Salim, Elliot Baerman, Carolina Colli Cruz, Cristina Natha, Varun Vemulapalli, Garrett Coleman, Krishnavathana Varatharajalu, Christopher Fan, Pablo Okhuysen, Anthony J. Olszanski, Yan Zhou, Hao Chi Zhang, Mehnaz Shafi, Yinghong Wang   +23 more
wiley   +1 more source

Caring at the transition: success and financial barriers of fidaxomicin discharge prescriptions for inpatients with Clostridioides difficile infection

Antimicrobial Stewardship & Healthcare Epidemiology
This retrospective cohort study evaluated the proportion of inpatients initiated and successfully discharged on fidaxomicin for Clostridioides difficile infection.
Ellen Earle, Jigar Mehta, Alexis Blecher, Matthew Shou Lun Lee   +3 more
doaj   +1 more source

Updated Management Guidelines for Clostridioides difficile in Paediatrics

Pathogens, 2020
Clostridioides difficile, formerly known as Clostridium difficile, causes infections (CDI) varying from self-limited diarrhoea to severe conditions, including toxic megacolon and bowel perforation.
Margherita Gnocchi, Martina Gagliardi, Pierpacifico Gismondi, Federica Gaiani, Gian Luigi de’ Angelis, Susanna Esposito   +5 more
doaj   +1 more source

Evaluating Effects of Antibiotics Across Preclinical Models of the Human Gastrointestinal Microbiota

MicrobiologyOpen, Volume 14, Issue 4, August 2025.
We compared microbiota changes following antibiotic treatment in two preclinical models of the human GI microbiota, minibioreactor arrays (MBRAs) and human microbiota associated mice (HMAmice). MBRAs and HMAmice were colonized with feces from 12 or 3 healthy humans, respectively, before treatment with each of 12 or 6 antibiotics.
Thomas A. Auchtung, Armando I. Lerma, Keegan Schuchart, Jennifer M. Auchtung   +3 more
wiley   +1 more source

High‐Throughput Tiling of Essential mRNAs Increases Potency of Antisense Antibiotics

Advanced Science, Volume 12, Issue 28, July 24, 2025.
The systematic tiling of essential genes’ mRNA here presented, proposes a valuable tool for the identification of novel PNA sequences with antibiotic potential. The high‐throughput synthetic set up opens the door to investigating thousands of sequences in an economic way and ultimately identifies potent antisense oligonucleotides while also giving room
Giorgia Danti, Linda Popella, Jörg Vogel, Hans M. Maric   +3 more
wiley   +1 more source

Piscidins synergize with fidaxomicin.

Culture density after overnight growth in the presence of the indicated concentrations of fidaxomicin and sub-inhibitory concentrations of (A) p1 or p1-Cu2+complex or (B) p3 or p3-Cu2+complex.
Asia Poudel (17827406), Adenrele Oludiran (17827388), Albert Siryapon (17827403), Yonghan Wu (17827397), Kwincy Alleyne (17827409), Savion Adams (17827412), Areej Malik (17827391), Andriana C. Zourou (17827394), David S. Courson (17827415), Myriam L. Cotten (1310271), Steven P. Gross (17827400), Erin B. Purcell (2277322)   +11 more
core   +1 more source